<< مقالات لاتين >>
<< بر اساس عنوان >>
1
pH Affects the Thermal Inactivation Parameters of R-Phycoerythrin from Porphyra yezoensis
2
pH and biogeochemical processes in the Gotland Basin of the Baltic Sea
3
pH and buffering capacity problems involved in the determination of ammonia in saline water using the indophenol blue spectrophotometric method
4
pH and buffering capacity problems involved in the determination of ammonia in saline water using the indophenol blue spectrophotometric method Original Research Article
5
pH and electro-responsive release behavior of MWCNT/PVA/PAAc composite microcapsules
6
pH- and glucose-sensitive glycopolymer nanoparticles based on phenylboronic acid for triggered release of insulin
7
pH and glutathion-responsive hydrogel for localized delivery of paclitaxel
8
pH and grain-size variation in leaching tests with bricks made of harbour sediments compared to commercial bricks
9
pH and heat-induced structural changes of bovine apo-α-lactalbumin
10
pH and hydrogen peroxide dual responsive supramolecular prodrug system for controlled release of bioactive molecules
11
pH and ionic strength effect on single fibrinogen molecule adsorption on mica studied with AFM
12
pH- and metal-dependent structural diversity from mononuclear to two-dimensional polymers based on a flexible tricarboxylate ligand
13
pH- and mol-ratio dependent formation of zinc(II) coordination polymers with iminodiacetic acid: Synthesis, spectroscopic, crystal structure and thermal studies
14
pH- and mol-ratio dependent tungsten(VI)–citrate speciation from aqueous solutions: syntheses, spectroscopic properties and crystal structures
15
pH and pCO2 microelectrode measurements and the diffusive behavior of carbon dioxide species in coastal marine sediments
16
pH and redox-responsive mixed micelles for enhanced intracellular drug release
17
pH and salt effects on chiral separations using affinity ultrafiltration Original Research Article
18
pH and salt responsive poly(N,N-dimethylaminoethyl methacrylate) cylindrical brushes and their quaternized derivatives
19
pH and salt-induced reversible aggregation of nonionic synthetic glycolipid vesicles
20
pH and solute concentration of suspension media affect the outcome of high hydrostatic pressure treatment of Listeria monocytogenes
21
pH- and sugar-sensitive layer-by-layer films and microcapsules for drug delivery
22
pH and surface tension dependence of mixed sodium deoxycholate–sodium dehydrocholate pre-micellar aggregation in aqueous solution
23
pH and temperature dependence of particle size in Pb1−xFexS nanoparticle films
24
pH and temperature dependent facile precipitation of nano-goethite particles in Fe(NO3)3–NaOH–NH3NH2HSO4–H2O medium
25
pH and temperature responsive porous membranes via an in situ bulk copolymerization approach
26
pH- and temperature-dependent release from cationic vesicles coexisting with copolymer of N-isopropylacrylamide and methacrylic acid
27
pH- and temperature-responsive amphiphilic diblock copolymers of 4-vinylpyridine and oligoethyleneglycol methacrylate synthesized by RAFT polymerization
28
pH- and temperature-responsive hydrogels from crosslinked triblock copolymers prepared via consecutive atom transfer radical polymerizations
29
pH- and temperature-responsive poly(aspartic acid)-l-poly(N-isopropylacrylamide) conetwork hydrogel
30
pH- and temperature-sensitive multiblock copolymer hydrogels composed of poly(ethylene glycol) and poly(amino urethane)
31
pH- and temperature-sensitive permeation through polyelectrolyte complex films composed of chitosan and polyalkyleneoxide–maleic acid copolymer
32
pH- and thermo-multi-responsive fluorescent micelles from block copolymers via reversible addition fragmentation chain transfer (RAFT) polymerization
33
pH- and thermo-responsive microcontainers as potential drug delivery systems: Morphological characteristic, release and cytotoxicity studies
34
pH- and thermosensitive thin lipid layer coated mesoporous magnetic nanoassemblies as a dual drug delivery system towards thermochemotherapy of cancer
35
pH- and time-dependent hemoglobin transitions: A case study for process modelling Original Research Article
36
p–H and T–S diagrams of 3He from 0.2 K to 20 K Original Research Article
37
pH changes in peralkaline late-magmatic fluids
38
pH changes of self-etching primers mixed with powdered dentine
39
pH control for enhanced reductive bioremediation of chlorinated solvent source zones Original Research Article
40
pH control of the structure, composition, and catalytic activity of sulfated zirconia
41
pH control on oxygen isotopic composition of symbiotic corals
42
pH control strategy in astaxanthin fermentation bioprocess by Xanthophyllomyces dendrorhous
43
pH control strategy of batch microbial transglutaminase production with Streptoverticillium mobaraense
44
pH control: handling nonlinearity and deadtime with fuzzy relational model-based control
45
pH controlled condensation of polysiloxane networks at the water–air interface
46
pH Controlled Dispersion of Non-oxide Ceramic Powders in Aqueous Media
47
pH Controlled Dispersion of Non-oxide Ceramic Powders in Aqueous Media
48
pH controlled emission of ruthenium(II)–tris–bipyridine complexes
49
pH controlled selective transport of proteins through charged ultrafilter membranes under coupled driving forces: An efficient process for protein separation
50
pH controlled size/shape in CTAB micelles with solubilized polar additives: A viscometry, scattering and spectral evaluation
51
pH controlled supramolecular structures of new silver(I) complexes based on 2-sulfoterephthalic acid and 4,4′-bipyridine
52
pH controls over anaerobic carbon mineralization, the efficiency of methane production, and methanogenic pathways in peatlands across an ombrotrophic–minerotrophic gradient
53
pH controls over anaerobic carbon mineralization, the efficiency of methane production, and methanogenic pathways in peatlands across an ombrotrophic–minerotrophic gradient
54
pH dependant sticking probability of gold colloid on silicon
55
pH dependence and thermodynamics of Hg(II) adsorption onto chitosan-poly(vinyl alcohol) hydrogel adsorbent
56
pH dependence of electrokinetic behavior of dolomite and magnesite in aqueous electrolyte solutions
57
pH Dependence of ferrous sorption onto two smectite clays
58
pH dependence of heme electrochemistry in cytochromes investigated by multiconformation continuum electrostatic calculations
59
pH Dependence of inhibitors targeting the occluding loop of cathepsin B
60
pH dependence of PDMS–PMAA IPN morphology and transport properties
61
pH Dependence of reactive sites of curcumin possessing antioxidant activity and free radical scavenging ability studied using the electrochemical and ESR techniques: Polyaniline used as a source of the free radical
62
pH dependence of steroid hormone—organic matter interactions at environmental concentrations Original Research Article
63
pH dependence of tailing in reversed-phase chromatography of a cationic dye: measurement of the strong adsorption site surface density
64
pH dependence of the absorption and emission behaviour of lumiflavin in aqueous solution
65
pH dependence of the composition and stability of MnIII–bicarbonate complexes and its implication for redox interaction of MnII with photosystem II
66
pH dependence of the dissociation of multimeric hemoglobin probed by high hydrostatic pressure Original Research Article
67
pH dependence of the fluorescence lifetime of enhanced yellow fluorescent protein in solution and cells
68
pH Dependence of the Folding of Intestinal Fatty Acid Binding Protein
69
pH dependence of the hydrophobicity of β-blocker amine compounds measured by counter-current chromatography
70
pH Dependence of the rate of DNA alkylation for (+)-duocarmycin SA and (+)-CCBI-TMI
71
pH Dependence of the Reaction Rate ofp-Bromophenacyl Bromide and of the Binding Constants of Ca2+and an Amide-Type Substrate Analog to Bovine Pancreatic Phospholipase A2
72
pH dependence of the reactions of arsenazo III with the lanthanides
73
pH dependency of ligand binding to cellobiohydrolase 1 (Cel7A): Affinity, selectivity and inhibition for designed propranolol analogues
74
pH dependency of serum ionised calcium Original Research Article
75
pH dependent binding of chlorin-p6 with phosphatidyl choline liposomes
76
pH Dependent binding of chlorin-p6 with phosphatidyl choline liposomes: Comparison between one and two-photon excited fluorescence
77
pH dependent conformational and structural changes of xylanase from an alkalophilic thermophilic Bacillus sp (NCIM 59)
78
pH dependent copper binding properties of a CuA azurin variant with both bridging cysteines replaced with serines
79
pH dependent dynamic behavior of flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD) in femtosecond to nanosecond time scale
80
pH dependent fluorescence switching in salicylideneaniline: ‘off–on–off’ operation controlled by surfactant micelles
81
pH Dependent formations of dinuclear molybdenum(V) and incomplete cubane molybdenum(IV) complexes with nitrilotriacetate
82
pH dependent growth of poly(L-lysine)/poly(L-glutamic) acid multilayer films and their cell adhesion properties
83
pH dependent interaction of biofunctionalized CdS nanoparticles with nucleobases and nucleotides: A fluorimetric study
84
pH dependent phosphate hydrolysis by a lanthanide EF-hand peptide
85
pH Dependent photophysics and role of medium on photoinduced electron transfer between ruthenium polypyridyl complex and anthraquinone
86
pH dependent protein stability: A quantitative approach based on Kramerʹs barrier escape
87
pH dependent reversible aggregation of Chitosan and glycol-Chitosan stabilized silver nanoparticles
88
pH dependent self assembly of (beta)-amyloid(10-35) and (beta)amyloid(10-35)-PEG3000
89
pH Dependent self-assembly of dimetallic lanthanide complexes
90
pH Dependent structural diversity of lead compounds based on new flexible ligand [3-(2-pyridyl)-1-pyrazolyl] acetic acid
91
pH dependent surface enhanced Raman study of Phe + Ag complex and DFT calculations for spectral analysis
92
pH dependent uptake of porphyrin-type photosensitizers by solid tumor cells in vitro is not induced by modification of transmembrane potential
93
PH Domain-Only Protein PHLDA3 Is a p53-Regulated Repressor of Akt
94
PH effect in the photocatalytic transformation of a phenyi-urea herbicide
95
pH effect on cysteine and cystine behaviour at hanging mercury drop electrode
96
pH effect on OH radical production in photo/ferrioxalate system
97
pH Effect on the binding of chlorin derivatives with Cremophor EL, a potential drug delivery vehicle
98
pH effect on the electrochemical redox reaction of disulfide with polyaniline film electrode in organic solution
99
pH Effect on the Size of Graphene Quantum dot Synthesized by Using Pulse Laser Irradiation
100
pH Effect on the spectroscopic behavior and photoinduced generation of semiquinone anion radical of hypocrellin B
101
pH effects on collagen fibrillogenesis in vitro: Electrostatic interactions and phosphate binding
102
pH effects on drug interactions with lipid bilayers by liposome electrokinetic chromatography
103
pH effects on optical and DNA binding properties of a thiophene-containing ruthenium(II) complex
104
pH effects on the adherence and fouling propensity of extracellular polymeric substances in a membrane bioreactor
105
pH effects on the binding of oxygen to non-vertebrate monomeric hemoglobins. A linked function model.
106
pH effects on the cellular uptake of four photosensitizing drugs evaluated for use in photodynamic therapy of cancer
107
pH effects on the hyaluronan hydrolysis catalysed by hyaluronidase in the presence of proteins. Part III. The electrostatic non-specific hyaluronan–hyaluronidase complex
108
pH effects on the hyaluronan hydrolysis catalysed by hyaluronidase in the presence of proteins: Part II. The electrostatic hyaluronan – Protein complexes
109
pH effects on the second-order nonlinear optical properties of surface modified CdS nanoparticles
110
pH evolution in sea ice grown at an outdoor experimental facility
111
P–H functionalised phosphinoalkoxides as ligands: synthesis and catalytic properties of [Cp2Zr(Me)(cyclo-1-O-2-PH(Tipp)-C6H10)] (Tipp=2,4,6-Pri3C6H2), [Cp2Zr(Me)(cyclo-1-O-2-PH(Tipp){Mo(CO)5}–C6H10)] and [Cp2Zr(BH4)(cyclo-1-O-2-PH(Mes)(BH3)–C6H10)] (Mes=2
112
pH gradient high-performance liquid chromatography: theory and applications
113
pH gradient reversed-phase liquid chromatography as a fractionation tool for the separation of peptides
114
pH has a role in cystic fibrosis infections
115
pH Heterogeneity of human and rabbit atherosclerotic plaques; a new insight into detection of vulnerable plaque
116
pH HOMEOSTASIS OF THE CIRCADIAN SPORULATION RHYTHM IN CLOCK MUTANTS OF NEUROSPORA CRASSA
117
pH Independent Complexation of 2-Aminobenzimidazole with β-cyclodextrin
118
pH indications in aqueous organic photodecompositions with carbonyl and hydroxyl groups
119
pH Induced Aggregation and Weak Gel Formation of Whey Protein Polymers
120
pH influence on root growth and nutrient uptake of Pinus pinaster seedlings
121
pH influence on sorption characteristics of heavy metal in the vadose zone
122
pH Influence on the stability of foams with protein–polysaccharide complexes at their interfaces
123
pH is a good predictor of the distribution of anoxygenic purple phototrophic bacteria in Arctic soils
124
pH is a good predictor of the distribution of anoxygenic purple phototrophic bacteria in Arctic soils
125
pH measurement and control in solvent extraction using column contractors
126
pH MEASUREMENT USING MICRO GAP STRUCTURE
127
pH Metric, Spectroscopic and Thermodynamic Study of Complexation Behavior of 2-aminobenzothiazole with Ni (II) in Presence of Amino Acids
128
pH microelectrode–micropipette system for the measurement of enzyme reactions in a picoliter volume of a living plant cell Original Research Article
129
pH modelling by neural networks. Application of control and validation data series in the Middle Loire river
130
pH modelling by neural networks. Application of control and validation data series in the Middle Loire river
131
pH Modulates the Quinone Position in the Photosynthetic Reaction Center from Rhodobacter sphaeroides in the Neutral and Charge Separated States
132
pH modulation of transport properties of alamethicin oligomers inserted in zwitterionic-based artificial lipid membranes Original Research Article
133
pH neutralization and influence on mechanical strength in self-adhesive resin luting agents
134
pH of activated carbon surface as an indication of its suitability for H2S removal from moist air streams Original Research Article
135
pH of seawater
136
pH of soul: How does acid-base balance affect our cognition?
137
pH of the Martian surface
138
pH optical sensors based on sol–gels: Chemical doping versus covalent immobilization Original Research Article
139
pH Oscillations and complex reaction dynamics in the non-buffered chlorite–thiourea reaction
140
pH polymeric membrane microelectrodes based on neutral carriers and their application in aquatic environments Original Research Article
141
pH pre-corrected liquid hot water pretreatment on corn stover with high hemicellulose recovery and low inhibitors formation
142
pH programming in capillary electrophoresis by means of temperature programming
143
pH regulates key players of nitrification in paddy soils
144
pH regulates key players of nitrification in paddy soils
145
pH regulation as a method of intensification of soil electroremediation
146
pH regulation during ischaemia-reperfusion of isolated rat hearts, and metabolic effects of 2,3-butanedione monoxime
147
pH Regulation in Anoxic Plants
148
pH regulation of alkaline wastewater with carbon dioxide: A case study of treatment of brewery wastewater in UASB reactor coupled with absorber
149
pH regulation of carbon and nitrogen dynamics in two agricultural soils
150
pH regulation of carbon and nitrogen dynamics in two agricultural soils
151
pH responsive “off–on–off” luminescent switch of a novel ruthenium(II) complex [Ru(bpy)2(pipipH2)]2+
152
pH responsive cross-linked polymeric matrices based on natural polymers: effect of process variables on swelling characterization and drug delivery properties
153
pH responsive itaconic acid grafted alginate microspheres for the controlled release of nifedipine
154
pH responsive luminescent switches of ruthenium(II) complexes containing two imidazole groups: Synthesis, spectroscopy, electrochemistry and theoretical calculations
155
pH Responsive micelle self-assembled from a new amphiphilic peptide as anti-tumor drug carrier
156
pH responsiveness of two-layer nano-composite membrane with ultrathin cylindrical nanopores PS-b-P4VP film
157
pH sensing in living cells using fluorescent microspheres
158
pH sensitive halloysite-sodium hyaluronate/poly(hydroxyethyl methacrylate) nanocomposites for colon cancer drug delivery
159
pH Sensitive Hydrogel Based Acrylic Acid for Controlled Drug Release
160
pH Sensitive Hydrogel Based on Poly(Acrylic Acid) and Cellulose Nanocrystals
161
pH sensitive N-succinyl chitosan grafted polyacrylamide hydrogel for oral insulin delivery
162
pH sensitive photoconductor based on poly(para-phenylene-vinylene)
163
pH sensitive photoconductor based on poly(para-phenylene-vinylene)
164
pH Sensitive polypropylene porous membrane prepared by grafting acrylic acid in supercritical carbon dioxide
165
pH sensitive silica nanotubes as rationally designed vehicles for NSAIDs delivery
166
pH Sensitive supramolecular assembling system between a new linear water soluble β-cyclodextrin terpolymer and an amphiphilic poly(ethylene oxide)
167
pH sensitivity of polyaniline and its substituted derivatives
168
pH sensor based on a detection sol–gel layer onto optical fiber
169
pH sensor based on deposited film of lead oxide on aluminum substrate electrode
170
pH sensor based on the crown heteropolyanion K28Li5H7P8W48O184·92H2O immobilized using a layer by layer assembly process
171
pH sensors with lithium lanthanum titanate sensitive material: applications in food industry
172
pH sequential ozonation of domestic and wine-distillery wastewaters
173
pH simulation model in a mixed layer of a lacustrine environment (the case of Lake Orta)
174
pH simulation model in a mixed layer of a lacustrine environment (the case of Lake Orta)
175
pH stress can cause cell elongation in Bacillus and Clostridium species: a research note
176
pH Switched sensitisation of europium(III) by a dansyl group
177
pH switching on-off semi-IPN hydrogel based on cross-linked poly(acrylamide-co-acrylic acid) and linear polyallyamine
178
pH transients in hydroxyapatite chromatography columns—Effects of operating conditions and media properties
179
pH Transients in hydroxyapatite chromatography columns—Experimental evidence and phenomenological modeling
180
pH transitions in cation exchange chromatographic columns containing weak acid groups
181
pH Transitions in Ion-Exchange Systems: Role in the Development of a Cation-Exchange Process for a Recombinant Protein
182
pH triggered release of protective poly(ethylene glycol)-b-polycation copolymers from liposomes
183
pH tunable morphology of the gold nanoparticles produced by citrate reduction
184
pH value and ionic strength effects on the adsorption kinetics of protein/phospholipid at the chloroform/water interface
185
pH Value controlled structures: from macrocyclic complex monomer to 2D macrocyclic sheet
186
pH value dependence of the photothermal and optical absorption spectra for polyaniline films
187
pH variability and CO2 induced acidification in the North Sea
188
pH, alkalinity and total CO2 in coastal seawater by potentiometric titration with a difference derivative readout Original Research Article
189
pH, Dissolved Oxygen, and Adsorption Effects on Metal Removal in Anaerobic Bioreactors
190
pH, Photo, and Aeration Period Effects on Arthrospira maxima Growth: Taguchi Technique
191
pH, serum proteins and ionic strength influence the uptake of merocyanine 540 by WiDr cells and its interaction with membrane structures
192
Ph.D. in Business Management at Istanbul University: A New Programme in English Ready to Commence in Fall 2016
193
Ph.D. in Nursing from Theory to Reality
194
Ph.D. Students of Irving Segal
195
pH/redox responsive core cross-linked nanoparticles from thiolated carboxymethyl chitosan for in vitro release study of methotrexate
196
pH/Temperature control of interpolymer complexation between poly(acrylic acid) and weak polybases in aqueous solutions
197
pH/temperature sensitive poly(ethylene glycol)-based biodegradable polyester block copolymer hydrogels
198
pH/temperature-responsive behaviors of semi-IPN and comb-type graft hydrogels composed of alginate and poly(N-isopropylacrylamide)
199
pH/temperature-sensitive 4-arm poly(ethylene glycol)-poly(amino urethane) copolymer hydrogels
200
Ph[PhC(O)NH]2PyNC(O)Ph: a new mesomeric stabilized azaylide. Synthesis, crystal structure and IR spectroscopic results
201
Ph[PhC(O)NH]2PyNC(O)Ph: a new mesomeric stabilized azaylide. Synthesis, crystal structure and IR spectroscopic results
202
Ph3BiCO3: a mild reagent for in situ oxidation of urazoles to triazolinediones
203
Ph3P/Br2/n-Bu4NNO2 as an efficient system for the preparation of N-nitrosamines and azides
204
PHA based denitrification: Municipal wastewater vs. acetate
205
PHA immune response assay in captive zebra finches is modulated by activity prior to testing
206
PHA production by mixed cultures: A way to valorize wastes from pulp industry
207
PHA production from wastewater by mixed microbial culture under short-term microbial enrichment
208
PHA stimulation may be useful for FDXR gene expression-based biodosimetry
209
PHA/IL2: An Efficient Mitogen Cocktail for Cytogenetic Studies of Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
210
PHA: A fast potential-based hierarchical agglomerative clustering method
211
PHAC SYNTHASES AND PHA DEPOLYMERASES: THE ENZYMES THAT PRODUCE AND DEGRADE PLASTIC
212
PHACE(S) syndrome: Report of a case with new ocular and systemic manifestations
213
PHACES (Photographs of Academic Clinicians and Their Educational Status): A Tool to Improve Delivery of Family-Centered Care
214
PHACES syndrome with cataract and Horner’s syndrome: a case report
215
Phaco chop: Matering technique, optimizing technology, and avoiding complication
216
Phacodynamic: An Apiration Flow v Vacuum Comparion
217
Phacodynamic: Matering the Tool and Technique of Phacoemulification urgery; Fourth Edition
218
Phacoemulification and len implantation after cleral buckling urgery
219
Phacoemulification Aociated Corneal Damage Evaluated by Corneal Volume
220
Phacoemulification cataract extraction and poterior chamber len implantation in patient with uveiti
221
Phacoemulification of Cataract in Patient Receiving Coumadin Therapy: Ocular and Hematologic Rik Aement Original Reearch Article
222
Phacoemulification v mall-Inciion Manual Cataract urgery: An Expert Trial
223
Phacoemulsification of bilateral cataracts in two pet rabbits
224
Phacomorphic Glaucoma as the First Manifestation of the Choroidal Malignant Melanoma
225
Phacotrabeculectomy and Implantation of Intraocular Lenses with Releasable Sutures and Antimetabolite Agents: Efficacy and Safety
226
Phacotrabeculectomy With Mitomycin C in Patient With Uveiti
227
Phae I/II randomized trial of intrahepatic arterial infuion chemotherapy with ciplatin and chemoembolization with ciplatin and polyvinyl ponge in patient with ocular melanoma metatatic to the liver
228
Phaehyphomycosis caused by Veronea bothryosa
229
Phaeoacremonium tuscanicum, a new fungal pathogen associated with oak decline in Zagros forests, Iran
230
Phaeochromocytoma
231
Phaeochromocytoma—views on current management
232
Phaeocystis blooms in the global ocean and their controlling mechanisms: a review
233
Phaeohyphomycosis caused by Diaporthe phaseolorum in an immunocompetent patient in Thailand: a case report
234
Phaeomoniella chlamydospora: causal agent of vine decline (Vitis vinifera) in the vineyards of Slovakia
235
Phaeophytins from Gossypium mustelinum Miers ex Watt (Malvaceae)
236
Phage adsorption to Lactobacillus plantarum: Influence of physiological and environmental factors
237
Phage coated magnetoelastic micro-biosensors for real-time detection of Bacillus anthracis spores
238
Phage Display and Crystallographic Analysis Reveals Potential Substrate/Binding Site Interactions in the Protein Secretion Chaperone CsaA from Agrobacterium tumefaciens
239
Phage display as a tool for the directed evolution of enzymes
240
Phage display combinatorial libraries of short peptides: ligand selection for protein purification
241
Phage display identifies an Eastern equine encephalitis virus glycoprotein E2-specific B cell epitope
242
Phage display identifies an Eastern equine encephalitis virus glycoprotein E2-specific B cell epitope
243
Phage display of functional, full-length human and viral membrane proteins
244
Phage Display Reveals Multiple Contact Sites between FhuA, an Outer Membrane Receptor of Escherichia coli, and TonB
245
Phage Display Screening Reveals an Association Between Germline-specific Transcription Factor Oct-4 and Multiple Cellular Proteins
246
Phage display selection and characterization of single-chain recombinant antibodies against Eimeria tenella sporozoites
247
Phage display selection and characterization of single-chain recombinant antibodies against Eimeria tenella sporozoites
248
Phage display techniques to obtain antibodies against turbot (Scophthalmus maximus) blood cells
249
Phage display technology for stem cell delivery and systemic therapy
250
Phage display technology: clinical applications and recent innovations
251
Phage FR38 Treatment on Sprague Dawley Rat Inferred from Blood Parameters and Organ Systems
252
Phage Genomics: Small Is Beautiful
253
Phage inactivation of foodborne pathogens on cooked and raw meat
254
Phage inactivation of Staphylococcus aureus in fresh and hard-type cheeses
255
Phage Integrases: Biology and Applications Review Article
256
Phage Langmuir monolayers and Langmuir–Blodgett films
257
Phage Like It HOT: Solution Structure of the Bacteriophage P1-Encoded HOT Protein, a Homolog of the θ Subunit of E. coli DNA Polymerase III
258
Phage ø29 DNA polymerase residues involved in the proper stabilisation of the primer-terminus at the 3′-5′ exonuclease active site
259
Phage P22 Procapsids Equilibrate with Free Coat Protein Subunits
260
Phage Peptide Libraries As a Source of Targeted Ligands
261
Phage selection for site-specific incorporation of unnatural amino acids into proteins in vivo Original Research Article
262
Phage Therapy in COVID-19 Treatment
263
Phage therapy: A modern tool to control bacterial infections
264
Phage therapy: assessment of the efficacy of a bacteriophage isolated in the treatment of salmonellosis induced by Salmonella enteritidis in mice
265
Phage therapy—advantages over antibiotics?
266
Phage Types of multidrug resistant Salmonella species in a rural area of Maharashtra, India
267
Phage types, virulence genes and PFGE profiles of Shiga toxin-producing Escherichia coli O157:H7 isolated from raw beef, soft cheese and vegetables in Lima (Peru)
268
Phage typing combined with pulsed-field gel electrophoresis and random amplified polymorphic DNA increases discrimination in the epidemiological analysis of Salmonella enteritidis strains
269
Phage typing, PCR amplification for mecA gene, and antibiotic resistance patterns as epidemiologic markers in nosocomial outbreaks of methicillin resistant Staphylococcus aureus
270
Phage versus Phagemid Libraries for Generation of Human Monoclonal Antibodies
271
Phage λ takes the first exit
272
Phage-based nanomaterials for biomedical applications
273
Phage-borne peptidomimetics as immunochemical reagent in dot-immunoassay for mycotoxin zearalenone
274
Phage-displayed Antibody Libraries of Synthetic Heavy Chain Complementarity Determining Regions
275
Phage-displayed peptide library screening for preferred human substrate peptide sequences for transglutaminase 7
276
Phage-displayed peptides that mimic zearalenone and its application in immunoassay
277
Phage-displayed protein chip based on SPR sensing
278
Phagemid Vectors for Phage Display: Properties, Characteristics and Construction Review Article
279
Phage-peptide Display Identifies the Interferon-responsive, Death-activated Protein Kinase Family as a Novel Modifier of MDM2 and p21WAF1
280
Phage-related DNA polymorphism in dairy and probiotic Lactobacillus
281
Phage-resistance linked to cell heterogeneity in the commercial strain Lactobacillus delbrueckii subsp. lactis Ab1
282
Phage-resistant mutants of Lactobacillus delbrueckii may have functional properties that differ from those of parent strains
283
Phagocyte functions in stressed rats: comparison of modulation by glutamine, arginine and ornithine 2-oxoglutarate
284
Phagocyte implications in advanced atherosclerosis
285
Phagocyte-derived S100 proteins in autoinflammation: Putative role in pathogenesis and usefulness as biomarkers
286
Phagocyte-Generated Superoxide Reduces Fe3+ to Displace It from the Surface of Asbestos
287
Phagocyte-induced lipid peroxidation of different intravenous fat emulsions and counteractive effect of vitamin E
288
Phagocyte–myocyte interactions and consequences during hypoxic wound healing
289
Phagocytes and oxidative stress
290
Phagocyte-specific S100 proteins: a novel group of proinflammatory molecules
291
Phagocytic Activity and IL-1 Alpha Levels for Asthma Patients
292
Phagocytic activity of alveolar macrophages toward polystyrene latex microspheres and PLGA microspheres loaded with anti-tuberculosis agent
293
Phagocytic Activity of Patients with a Diabetic Foot in Wasit Province, Iraq
294
Phagocytic activity of scallop (Pecten maximus) haemocytes maintained in vitro
295
Phagocytic activity of turbot (Scophthalmus maximus) leucocytes: opsonic effect of antibody and complement
296
Phagocytic activity of two lines of chickens divergently selected for antibody production
297
Phagocytic activity of two lines of chickens divergently selected for antibody production
298
Phagocytic and chemotactic responses of manila and carpet shell clam haemocytes against Vibrio tapetis, the causative agent of brown ring disease
299
Phagocytic and Metabolic Activities of Macrophages from Mummichog Naturally Exposed to Pulp Mill Effluents in the Miramichi River
300
Phagocytic capacity and apoptosis of peripheral blood cells from patients with iron deficiency anemia
301
Phagocytic cells of the thymic reticulum interact with thymocytes via extracellular matrix ligands and receptors
302
Phagocytic function and metabolite production in thioacetamide-induced liver cirrhosis: a comparative study in perfused livers and cultured Kupffer cells
303
Phagocytic killing of microorganisms by radical processes:consequences of the reaction of hydroxyl radicals with chloride yielding chlorine atoms
304
Phagocytic response of macrophages from the pronephros of American plaice (Hipoglossoides platessoides) exposed to contaminated sediments from Baie des Anglais, Quebec
305
Phagocytic Response of Terrestrial and Aquatic Invertebrates Following in Vitro Exposure to Trace Elements
306
Phagocytosis and development: back to the future
307
Phagocytosis and innate immunity
308
Phagocytosis and respiratory burst activity of haemocytes from the ivory snail, Babylonia areolata
309
Phagocytosis by B-cells and neutrophils in Atlantic salmon (Salmo salar L.) and Atlantic cod (Gadus morhua L.)
310
Phagocytosis in pup and adult harbour, grey and harp seals
311
Phagocytosis in pup and adult harbour, grey and harp seals
312
Phagocytosis inhibition of clam and mussel haemocytes by Perkinsus atlanticus secretion products.
313
Phagocytosis of Candida albicans by concanavalin-A activated peritoneal macrophages
314
Phagocytosis of Candida albicans by concanavalin-A activated peritoneal macrophages
315
Phagocytosis of candida albicans by lymphatic tumour cells in vitro
316
Phagocytosis of Candida albicans by metastatic and non metastatic human breast cancer cell lines in vitro
317
Phagocytosis of chemically modified carbon materials
318
Phagocytosis of Loma salmonae (Microsporidia) spores in Atlantic salmon (Salmo salar), a resistant host, and chinook salmon (Oncorhynchus tshawytscha), a susceptible host
319
Phagocytosis of N-acetyl-d-glucosamine particles, a Th1 adjuvant, by RAW 264.7 cells results in MAPK activation and TNF-α, but not IL-10, production
320
Phagocytosis of wear debris by osteoblasts affects differentiation and local factor production in a manner dependent on particle composition
321
Phagocytosis, endosomal/lysosomal system and other cellularaspects of macrophage activation by Canova medication
322
Phagocytotic removal of apoptotic endocrine cells by folliculostellate cells and its functional implications in clusterin accumulation in pituitary colloids in helmeted guinea fowl (Numida meleagris)
323
Phagostimulatory effect of uptake of PLGA microspheres loaded with rifampicin on alveolar macrophages
324
Phagotrophic algae in a wastewater stabilization pond
325
PHAHs in 14 principal river sediments from Hai River basin, China Original Research Article
326
Phakic Intraocular Lenses and their Special Indications
327
Phakic IOL: A photo finih?
328
Phakic poterior chamber intraocular len for the correction of aniometropia and treatment of amblyopia
329
Phakomatosis pigmentovascularis type IIa
330
Phalangeal osteochondroma: a cause of childhood trigger finger
331
Phalangeal osteosonogrammetry age-related changes and assessment of a Lebanese reference population
332
Phalangeal Tuberculosis After Mallet Finger Treatment: A Case Report
333
Phalangeal ultrasonography in forearm fracture discrimination
334
Phalanx-like osseous structure posterior to the cervical vertebrae: a hitherto unreported location for a rare anomaly
335
Phalaropes feeding at a coastal front in Santa Monica Bay, California
336
PHALEN TEST POSITIVATION TIME and ITS CORRELATION WITH ELECTRONEUROMYOGRAPHY
337
Phallometric testing with sexual offenders: Limits to its value
338
Phalloplasty for an amputated phallus in intersex patients
339
Phalloplasty in female-to-male transsexuals using free radial osteocutaneous flap: a series of 22 cases, ,
340
Phanerochaete chrysosporium pretreatment of biomass to enhance solvent production in subsequent bacterial solid-substrate cultivation
341
Phanerochaete flavido-alba ligninolytic activities and decolorization of partially bio-depurated paper mill wastes
342
Phanerozoic atmospheric CO2 change: evaluating geochemical and paleobiological approaches
343
Phanerozoic biodiversity: rocks or real?
344
Phanerozoic burial and unroofing history of the western Slave craton and Wopmay orogen from apatite (U–Th)/He thermochronometry
345
Phanerozoic changes in the high-rank suprageneric diversity structure of brachiopods: Linear and non-linear effects
346
Phanerozoic continental growth and gold metallogeny of Asia
347
Phanerozoic Continental Growth of East and Southeast Asia: Timings of Amalgamation and Accretion
348
Phanerozoic Geodynamic Evolution of the Circum-Italian Realm
349
Phanerozoic high-pressure eclogite and intermediate-pressure granulite facies metamorphism in the Gyeonggi Massif, South Korea: Implications for the eastward extension of the Dabie–Sulu continental collision zone
350
Phanerozoic hot spot traces and paleogeographic reconstructions of the Siberian continent based on interaction with the African large low shear velocity province
351
Phanerozoic Large Igneous Provinces (LIPs), HEATT (Haline Euxinic Acidic Thermal Transgression) episodes, and mass extinctions
352
Phanerozoic marine biodiversity follows a hyperbolic trend
353
Phanerozoic organic-carbon-rich marine sediments: Overview and future research challenges
354
Phanerozoic paleogeography, paleoenvironment and lithofacies maps of the circum-Atlantic margins
355
Phanerozoic polar wander, palaeogeography and dynamics
356
Phanerozoic reactivation along a fundamental Proterozoic crustal fault, the Darling River Lineament, Australia: constraints from apatite fission track thermochronology
357
Phanerozoic reactivation of the Archean North China Craton through episodic magmatism: Evidence from zircon U–Pb geochronology and Hf isotopes from the Liaodong Peninsula
358
Phanerozoic Reconstitution of Indian Shield as Aftermath of Gondwana Break-up
359
Phanerozoic tectonics of the South China Block: Key observations and controversies
360
Phanerozoic tectonothermal events of the Xuefengshan Belt, central South China: Implications from UPb age and LuHf determinations of granites
361
Phanerozoic, pre-Cretaceous thermotectonic events in southern Sweden revealed by fission track thermochronology
362
Phanerozoic, pre-Cretaceous thermotectonic events in southern Sweden revealed by fission track thermochronology
363
Phanquinone: a useful fluorescent pre-chromatographic derivatization reagent for liquid chromatographic analyses of amino acid dosage forms Original Research Article
364
PHANTASTICA Regulates Development of the Adaxial Mesophyll in Nicotiana Leaves
365
Phantom accretion by black holes and the generalized second law of thermodynamics
366
Phantom and in vivo study of the look–locher T1 mapping method
367
Phantom Archean crust in Mangaia hotspot lavas and the meaning of heterogeneous mantle
368
Phantom bursting is highly sensitive to noise and unlikely to account for slow bursting in -cells: Considerations in favor of metabolically driven oscillations
369
Phantom dosimeters examined by NMR analysis: a promising technique for 3-D determination of absorbed dose
370
Phantom elasticity reconstruction with Digital Image Elasto-Tomography
371
Phantom endometriosis of the sciatic nerve
372
Phantom evolution in power-law potentials Original Research Article
373
Phantom faces for face analysis
374
Phantom feelings in the thalamus explained
375
Phantom Friedmann cosmologies and higher-order characteristics of expansion
376
Phantom limb after stroke: An underreported phenomenon
377
Phantom limb pain
378
Phantom limb pain
379
Phantom limb pain in pediatric burn survivors
380
Phantom Limb Sensation (PLS) and Phantom Limb Pain (PLP) among Young Landmine Amputees
381
PHANTOM LIMB SYNDROME: A REVIEW
382
Phantom limbs – Or phantoms of phantom limbs?
383
Phantom maps and homology theories
384
Phantom Maps and Purity in Modular Representation Theory, III
385
Phantom maps and the Gray index
386
Phantom Maps in the Stable Module Category
387
Phantom materials for single point imaging pulse sequences
388
Phantom nurses at real bedsides
389
Phantom recall
390
Phantom reflexes: Muscle contractions at a frequency not physically present in the input stimuli
391
Phantom study of radiotracer concentration quantification in breast scintigraphy
392
Phantom thermodynamics Original Research Article
393
Phantom tumor of the lung in heart failure patient
394
Phantom Validation of Tc-99m Absolute Quantification in a SPECT/CT Commercial Device
395
PHANTOM: A Monte Carlo event generator for six parton final states at high energy colliders Original Research Article
396
Phantom: a simple and effective flow control scheme
397
Phantom-based performance evaluation: Application to brain segmentation from magnetic resonance images
398
Phantom-like behaviour in dilatonic brane-world scenario with induced gravity Original Research Article
399
Phantom-limb lengthening after heart transplant
400
Phantom-limb pain: characteristics, causes, and treatment
401
Phantom-node method for shell models with arbitrary cracks
402
Phantoms and spectres: capital and labour at the millennium
403
Phantoms of regularity in the sea of quantum chaos
404
PhAP protease from Pseudoalteromonas haloplanktis TAC125: Gene cloning, recombinant production in E. coli and enzyme characterization
405
Phar Lap and duodenitis-proximal jejunitis
406
Pharaoh and the Divine Wont of Respiting: A Critical Analysis of Quranic Themes
407
PHARAOH EAGLE-OWL BUBO ASCALAPHUS (SAVIGNY, 1809) (STRIGIFORMES, STRIGIDAE), THE “SHROUDED IN MYSTERY” OWL OF IRAQ and IRAN
408
Pharmaceutical Advances and Proteomics Researches
409
Pharmaceutical advertising versus research spending: are profits more important than patients?
410
Pharmaceutical analysis of 5-aminolevulinic acid in solution and in tissues
411
Pharmaceutical Analysis, D.C. Lee, M. Webb (Eds.). Blackwell Publishing Ltd, Oxford, UK (2003)
412
Pharmaceutical and Bio-analytical Applications of Ion Mobility Spectrometry for Determination of Clopidogrel (Plavix)
413
Pharmaceutical and biotechnological aerosols for cystic fibrosis therapy
414
Pharmaceutical and clinical aspects of p-phenylene-diamine patch test material
415
PHARMACEUTICAL AND CLINICAL EVALUATION OF INTRAVENOUS ADMIXTURE OF DOBUTAMINE AND DOPAMINE USED IN TREATMENT HYPOTENSION IN NEONATAL INTENSIVE CARE UNITS
416
Pharmaceutical and industrial protein engineering: Where we are?
417
Pharmaceutical and nutraceutical effects of Pinus pinaster bark extract
418
Pharmaceutical and nutraceutical management of canine osteoarthritis: Present and future perspectives
419
Pharmaceutical and personal care products (PPCPs) in urban receiving waters l
420
Pharmaceutical and personal care products in tile drainage following surface spreading and injection of dewatered municipal biosolids to an agricultural field Original Research Article
421
Pharmaceutical and Related Drugs
422
Pharmaceutical applications of a flurbiprofen sensor
423
Pharmaceutical applications of calorimetric measurements in the new millennium
424
Pharmaceutical applications of confocal laser scanning microscopy: The physical characterisation of pharmaceutical systems
425
Pharmaceutical applications of dynamic mechanical thermal analysis
426
Pharmaceutical applications of embryonic stem cells
427
Pharmaceutical applications of isoelectric focusing on microchip with imaged UV detection
428
Pharmaceutical applications of magnetic resonance imaging (MRI)
429
Pharmaceutical applications of Mid-IR and Raman spectroscopy
430
Pharmaceutical applications of some spanish clays (sepiolite, palygorskite, bentonite): some preformulation studies
431
Pharmaceutical applications of various natural gums, mucilages and their modified forms
432
Pharmaceutical Approaches and Advancements in Male Contraception
433
Pharmaceutical aspects of parenteral nutrition: from now to the future
434
Pharmaceutical Care Approach to Hearing Loss
435
Pharmaceutical Care Education and Practice in Jordan in the New Millennium
436
Pharmaceutical care impact on health-related quality of life (HRQOL) and pharmaco-economical burden on COVID recovered diabetic patients with comorbid condition
437
Pharmaceutical Care Program for Patients With Uncontrolled Hypertension: Report of a Double-Blind Clinical Trial With Ambulatory Blood Pressure Monitoring
438
Pharmaceutical challenges in veterinary product development
439
Pharmaceutical Characterization and in vivo Evaluation of the Possible Anti-Inflammatory Effect of Topical Allopurinol Gel in an Animal Model
440
Pharmaceutical Characterization of Aqueous Stem Bark Extract of Bridelia ferruginea Benth (Euphorbiaceae)
441
Pharmaceutical chemicals and endocrine disrupters in municipal wastewater in Tokyo and their removal during activated sludge treatment
442
Pharmaceutical Cocrystal of Piroxicam: Design, Formulation and Evaluation
443
Pharmaceutical Co-Crystallization: Regulatory Aspects, Design, Characterization, and Applications
444
Pharmaceutical Cocrystals: Regulatory and Strategic Aspects, Design and Development
445
Pharmaceutical companies and the third world
446
Pharmaceutical companies pay criminal fine for fxobal price fixing
447
Pharmaceutical companies pledge vaccines for developing countries
448
Pharmaceutical companies target plant products for drugs of the future
449
Pharmaceutical company trials and the integrity of medical research
450
Pharmaceutical Compounds as Photostabilizers
451
Pharmaceutical cost management and access to psychotropic drugs: The U.S. context
452
Pharmaceutical economy and the economic assessment of drugs in France
453
Pharmaceutical Electrochemistry: the Electrochemical Behaviour of Paracetamol at ZnO Nanoparticales/1, 2-Napthaquinone-4-Sulphonic Acid Glassy Carbon Modified Electrode
454
Pharmaceutical Equivalence of Some Commercial Samples of Artesunate and Amodiaquine Tablets Sold in Southwestern Nigeria
455
Pharmaceutical Evaluation of Metformin HCl Products Available in the Jordanian Market
456
Pharmaceutical Evaluation of Ziziphus Jujuba Mucoadhesive Buccal Film
457
Pharmaceutical Excipient Development: The Need for Preclinical Guidance
458
Pharmaceutical Formulation of Garlic and Turmeric Dried Crude Extract and Their Synergistic Antifungal Activity and Safety
459
Pharmaceutical haute couture: educating patients about health-care choices
460
Pharmaceutical impurities: Analytical, toxicological and regulatory perspectives
461
Pharmaceutical impurities: Regulatory perspective for Abbreviated New Drug Applications
462
Pharmaceutical industry profits and cost to senior citizensʹ health
463
Pharmaceutical Industry Roundtable Abstracts
464
Pharmaceutical innovation and longevity growth in 30 developing and high-income countries, 2000–2009
465
Pharmaceutical laws and regulations in Iran: An overview
466
Pharmaceutical microcalorimetry: recent advances in the study of solid state materials
467
Pharmaceutical Nanoemulsions and Their Potential Topical and Transdermal Applications
468
Pharmaceutical Nanoparticles and the Mucin Biopolymer Barrier
469
Pharmaceutical nanotechnology for oral delivery of anticancer drugs
470
Pharmaceutical Nickel(II) Chelation Properties of 3-Hydroxyflaven, Deferiprone and Maltol Metal Chelators: A Density Functional Study
471
Pharmaceutical patent analyst – FutureScience publishing
472
Pharmaceutical patents on plant derived materials in Brazil: Policy, law and statistics
473
Pharmaceutical policies used by private health insurance companies in Saudi Arabia
474
Pharmaceutical powder technology — from art to science: the challenge of the FDAʹs Process Analytical Technology initiative
475
Pharmaceutical powders analysis using FT-Raman spectrometry: Simultaneous determination of sulfathiazole and sulfanilamide
476
Pharmaceutical powders compaction: Experimental and numerical analysis of the density distribution
477
pharmaceutical prescription (Rx): Calcium, phosphate, and secundum artem
478
Pharmaceutical profiling method for lipophilicity and integrity using liquid chromatography–mass spectrometry
479
Pharmaceutical Properties of Hibiscus sabdariffa, Toward an Ideal Treatment for Hypertension
480
Pharmaceutical reform and physician strikes in Korea: separation of drug prescribing and dispensing
481
Pharmaceutical representatives
482
Pharmaceutical representatives’ beliefs and practices about their professional practice: a study in Sudan
483
Pharmaceutical Research in Wilhelmine Germany: The Case of E. Merck
484
Pharmaceutical research: paradox, challenge or dilemma?
485
Pharmaceutical risk management in Turkey: The first national overview
486
Pharmaceutical Statistics Using SAS®: A Practical Guide by Alex Dmitrienko, Christy Chuang-Stein, Ralph DʹAgostino
487
Pharmaceutical strategic purchasing requirements in Iran: Price interventions and the related effective factors
488
Pharmaceutical Strategic Purchasing: a Key to Improve Access to Medicines
489
Pharmaceutical supply chain risks: a systematic review
490
Pharmaceutical toxicology: Designing studies to reduce animal use, while maximizing human translation
491
Pharmaceutical trace analysis in aqueous environmental matrices by liquid chromatography–ion trap tandem mass spectrometry
492
Pharmaceutical Wastewater Chemical Oxygen Demand Reduction: Electro-Fenton, UV-enhanced Electro-Fenton and Activated Sludge
493
Pharmaceutical wastewater treatment by membrane bioreactor process – a case study in southern Taiwan Original Research Article
494
Pharmaceutical workers
495
PHARMACEUTICAL, FOOD AND NON-FOOD APPLICATIONS OF MODIFIED STARCHES: A CRITICAL REVIEW
496
Pharmaceutical-enantiomers resolution using immobilized polysaccharide-based chiral stationary phases in supercritical fluid chromatography
497
Pharmaceuticals and personal care products (PPCPs) and endocrine disrupting chemicals (EDCs) in stormwater canals and Bayou St. John in New Orleans, Louisiana, USA
498
Pharmaceuticals and personal care products (PPCPs) in foods. Potential risks to human health?
499
Pharmaceuticals and personal care products (PPCPs) in surface and treated waters of Louisiana, USA and Ontario, Canada
500
Pharmaceuticals and personal care products (PPCPs) in treated wastewater discharges into Charleston Harbor, South Carolina Original Research Article
501
Pharmaceuticals and the Strategic National Stockpile Program
502
Pharmaceuticals in Australia: developments in regulation and governance
503
Pharmaceuticals in groundwaters: Analytical methods and results of a monitoring program in Baden-Württemberg, Germany
504
PHARMACEUTICALS IN IRAN: AN OVERVIEW
505
Pharmaceuticals in STP effluents and their solar photodegradation in aquatic environment
506
Pharmaceuticals in the aquatic environment––a comparison of risk assessment strategies
507
Pharmaceuticals in the river Elbe and its tributaries
508
Pharmaceuticals Safety Practices-A Comparative Pilot Study
509
Pharmaceuticals Solubility is Still Nowadays Widely Studied Everywhere
510
Pharmaceuticals, alkylphenols and pesticides in Mediterranean coastal waters: Results from a pilot survey using passive samplers
511
Pharmaceuticals, hormones and bisphenol A in untreated source and finished drinking water in Ontario, Canada — Occurrence and treatment efficiency Original Research Article
512
Pharmaceuticals, personal care products and endocrine-disrupting chemicals in U.S. surface and finished drinking waters: A proposed ranking system Original Research Article
513
Pharmaceuticals: a threat to drinking water? Original Research Article
514
Pharmaceuticals—our true clinical partners?
515
Pharmaciesʹ over-the-counter drug monopoly in Denmark ended
516
Pharmacies, self-medication and pharmaceutical marketing in Bombay, India
517
Pharmacist and nurse: a team approach towards primary health care or a convenient “therapeutic alliance”? Original Research Article
518
Pharmacist Interventions in Improving Clinical Outcomes in Patients with Type 2 Diabetes Mellitus Among the Underrepresented Population: A Collaborative Ambulatory Care Pharmacy Practice (CAPP) Approach
519
PHARMACIST ROLE IN GLOBAL HEALTH: A REVIEW OF LITERATURE
520
Pharmacist, the pharmaceutical industry and pharmacy education in Saudi Arabia: A questionnaire-based study
521
Pharmacist’s knowledge, practice and attitudes toward pharmacovigilance and adverse drug reactions reporting process
522
Pharmacist-Led Medication Review: Supports for New Role of Pharmacists
523
PHARMACIST-MANAGED THERAPEUTIC DRUG MONITORING SERVICE FOR ANTIEPILEPTIC DRUGS AND IMPROVED SEIZURE CONTROL
524
Pharmacist-Physician Organic Cooperation Is an Effective Strategy to Reduce the Medication-related Problems, An Experience in CKD Patients
525
Pharmacists agree: stop the pharmacy madness
526
Pharmacists as Entrepreneurs or Employees: The Role of Locus of Control
527
Pharmacists Remuneration Models in Iran and Selected Countries: a Comparative Study
528
PHARMACISTS UNDERSTANDING AND ATTITUDES TOWARDS PHARMACEUTICAL CARE IN SAUDI ARABIA
529
Pharmacists’ and physicians’ perception and exposure to drug promotion: A Saudi study
530
Pharmacists’ Attitudes and Perceived Barriers about Community Pharmacy-Based Cardiovascular Risk Screening Services
531
PHARMACISTS’ NEGLIGENCE AND PRINCIPLES OF LIABILITY
532
Pharmacists’ Perception of the Sale of Non-Clinically Proven Health Supplements in Penang, Malaysia
533
Pharmaco1logic Evaluation of the Calcitonin Analogue SB 205614 in Models of Osteoclastic Bone Resorption In Vitro and In Vhro: Comparison With Salmon Calcitonin and Elcatonin
534
Pharmacodynamic activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or micronised fenofibrate (200 mg/day) therapy for 23 days
535
Pharmacodynamic and/or pharmacokinetic characteristics of interactions between loreclezole and four conventional antiepileptic drugs in pentylenetetrazole-induced seizures in mice: An isobolographic analysis
536
Pharmacodynamic Effect of N-Acetylcysteine as Adjunctive Therapy in Mild Systemic Lupus Erythematosus Patients
537
Pharmacodynamic effects of milrinone with and without a bolus loading infusion
538
Pharmacodynamic Effects of Prasugrel Dosing Regimens in Patients on Maintenance Prasugrel Therapy: Results of a Prospective Randomized Study
539
Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Patients With Stable Coronary Artery Disease: Results of the SWAP-2 Study (Switching Anti Platelet-2)
540
PHARMACODYNAMIC INTERACTION OF GARLIC WITH PROPRANOLOL IN ISCHEMIA-REPERFUSION INDUCED MYOCARDIAL DAMAGE
541
Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects Original Research Article
542
Pharmacodynamic interactions of amodiaquine and its major metabolite desethylamodiaquine with artemisinin, quinine and atovaquone in Plasmodium falciparum in vitro
543
Pharmacodynamic profile of short-term readministration of abciximab in healthy subjects
544
Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide
545
Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniae
546
Pharmacodynamic study on acute hypotensive activities of Carissa carandas extract in normal rats
547
Pharmacodynamic–pharmacokinetic profiles of metformin hydrochloride from a mucoadhesive formulation of a polysaccharide with antidiabetic property in streptozotocin-induced diabetic rat models
548
Pharmacodynamics and microbiology of trovafloxacin in animal models of surgical infection
549
Pharmacodynamics and pharmacokinetics of cefoperazone and cefamandole in dogs following single dose intravenous and intramuscular administration
550
Pharmacodynamics and pharmacokinetics of flumequine in pigs after single intravenous and intramuscular administration
551
Pharmacodynamics and pharmacokinetics of single doses of subcutaneous pegylated human G-CSF mutant (Ro 25-8315) in healthy volunteers: Comparison with single and multiple daily doses of ilgrastim
552
Pharmacodynamics in the elderly
553
Pharmacodynamics of alpha2-adrenoceptor agonists
554
Pharmacodynamics of antimicrobial therapy in surgery
555
Pharmacodynamics of immunosuppressive drugs
556
Pharmacodynamics of Intermittent- and Continuous-Infusion Gefepime Alone and in Combination with Once-Daily Tobramycin against Pseudomonas aeruginosa in an in vitro Infection Model
557
Pharmacodynamics of mivacurium in severely burned patients
558
Pharmacodynamics of warfarin in cats
559
Pharmacodynamics Studies on Ricobendazole In Male Rats
560
Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8-mg dose of cerivastatin in patients with primary hypercholesterolemia
561
Pharmacodynamics: Relation to antimicrobial resistance
562
Pharmacodynamics: Relation to Antimicrobial Resistance
563
Pharmacoeconomic Aspects of Treating Hemorrhoidal Disease-Cost of Illness Study Based on Data from Balkan Country with Recent History of Social and Economic Transition
564
Pharmacoeconomic assessment of midazolam in two emergency departments
565
Pharmacoeconomic Education for Pharmacy Students in Bosnia and Herzegovina
566
Pharmacoeconomic Evaluation of Anti-Diabetic Therapy in A Nigerian Tertiary Health Institution
567
Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes
568
Pharmacoeconomic Impact Evaluation of Statin Adherence in High-risk Unselected Post Myocardial Infarction Population: an Administrative Database-guided Analysis
569
Pharmaco-economic issues for diabetes therapy
570
Pharmacoeconomic issues in antihypertensive therapy
571
Pharmacoeconomic study of antibiotics used in the treatment of lower respiratory tract infections in ICU patients: A case study in an Egyptian hospital
572
Pharmacoeconomics Analysis in a Pediatric Population
573
Pharmaco-economics analysis, as a strategy on facilitating choices between health and non-health programs in the establishment of the national health care system
574
Pharmacoeconomics and health outcomes: state of the art
575
Pharmacoeconomics and Utilization of Intravenous Iron Sucrose in a Tertiary Care Hospital
576
Pharmacoeconomics and Utilization of Intravenous Proton Pump Inhibitors in a Tertiary Care Hospital
577
Pharmacoeconomics for surgeons
578
Pharmacoeconomics in Iran: It Is Time to Take It into Practice
579
Pharmacoeconomics of Angiotensin Converting Enzyme Inhibitors in Heart Failure
580
PHARMACO-ECONOMICS OF MICRODOSING CLINICAL TRIALS IN DRUG DEVELOPMENT PROCESS
581
Pharmacoeconomics of pneumonia
582
Pharmacoeconomics: what is it and where is it going?
583
Pharmacoeconomics; an Appropriate Tool for Policy Makers or Just a New Field of Research in Iran?
584
Pharmaco-EEG-based assessment of interaction between ethanol and levetiracetam
585
Pharmacoepidemiological study of self-medication in adults attending pharmacies in Alexandria, Egypt
586
Pharmacoepidemiology of Drugs Used in Indoor Patients of Orthopaedic Department at a Tertiary Care Hospital
587
Pharmacoepidemiology Safety Study of Fibrate and Statin Concomitant Therapy
588
Pharmacogenetic Effect of Thiopurine Methyl Transferase (TPMT) Gene Expression and Serum TNF on the Imuran Response in Ulcerative Colitis (UC) Iraqi Patients
589
Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure Original Research Article
590
Pharmacogenetic prediction of clozapine response Original Research Article
591
Pharmacogenetic Studies of Depression
592
Pharmacogenetic Testing for Warfarin Dosing Still Awaits Validation
593
Pharmacogenetic variation of SLC47A1 gene and metformin response in type2 diabetes patients
594
Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450–metabolized drugs
595
Pharmacogenetics and adverse drug reactions
596
Pharmacogenetics and antipsychotic drugs
597
Pharmacogenetics and drug-induced nephrotoxicity in renal transplant recipients
598
Pharmacogenetics and future drug development and delivery
599
Pharmacogenetics and Personalized Medicine in Pancreatic Cancer
600
Pharmacogenetics draws an ACE
601
Pharmacogenetics in Cardiovascular Antithrombotic Therapy
602
Pharmacogenetics of anti-estrogen treatment of breast cancer
603
Pharmacogenetics of antipsychotic treatment: lessons learned from clozapine
604
Pharmacogenetics of clozapine response
605
Pharmacogenetics of CYP enzymes and drug transporters: remarkable recent advances
606
Pharmacogenetics of disease-modifying anti-rheumatic drugs
607
Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management
608
Pharmacogenetics of inflammatory bowel disease
609
Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother
610
Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy
611
Pharmacogenetics, the Promise of Translating Personalized Medicine into Clinical Pediatrics
612
Pharmacogenetics: Fitting the Drug to the Patient
613
Pharmacogenetics: Is the right drug for the right patient sufficient?
614
Pharmacogenetics: Yeast Lead the Way
615
Pharmacogenetics-Oriented Therapeutic Drug Monitoring of Digoxin in Critically ILL Patients
616
Pharmacogenetics-Oriented Therapeutic Drug Monitoring of Digoxin in Critically ILL Patients
617
Pharmacogenomic approaches in the treatment of breast cancer by tamoxifen
618
Pharmacogenomic determination of genes associated with sensitivity or resistance of tumor cells to curcumin and curcumin derivatives
619
Pharmacogenomic profiling of an oxidative stress-mediated spongiform encephalopathy
620
Pharmacogenomic Profiling of the PI3K/PTEN Pathway in Sporadic Breast Cancer
621
Pharmacogenomics and -genetics in colorectal cancer
622
Pharmacogenomics and the Failing Heart: Are We Waiting for Godot?
623
Pharmacogenomics for Infectious Diseases
624
pharmacogenomics implementation and hurdles to overcome; in the context of a developing country
625
Pharmacogenomics in bladder cancer
626
Pharmacogenomics in bladder cancer
627
Pharmacogenomics in Cancer Chemotherapy
628
Pharmacogenomics in cancer drug discovery and development: inhibitors of the Hsp90 molecular chaperone
629
Pharmacogenomics in non-small-cell lung cancer chemotherapy
630
Pharmacogenomics of organic anion-transporting polypeptides (OATP)
631
Pharmacogenomics- The Promise of Personalized Medicine
632
Pharmacogenomics: New paradigms for targeted therapy based on individual response to drugs
633
Pharmacogenomics: New paradigms for targeted therapy based on individual response to drugs
634
Pharmacogenomics: out of the lab and into the community
635
Pharmacognostic and Acute Toxicity Study of Burkea Africana Root
636
Pharmacognostic and AntiInflammatory Properties of Securigera securidaca Seeds and Seed Oil
637
Pharmacognostic and Elemental Analysis of the Leaves of Tapinanthus globifer (A. Rich). Tiegh
638
Pharmacognostic and Physico-chemical Investigation of Barleria cristata Linn. (Leaf) for Quality Control Assessment
639
Pharmacognostic and phytochemical investigation of Heracleum persicum Desf. ex Fischer
640
Pharmacognostic and Preliminary Phytochemical Investigation on Doronicum scorpioides Roots
641
Pharmacognostic Characteristics and Mutagenic Studies of Alstonia boonei De Wild
642
Pharmacognostic Characteristics of Hibiscus sabdariffa L. as a Means of Monitoring Quality
643
Pharmacognostic evaluation and physico-chemical analysis of Lantana camara (Linn.) flowers
644
Pharmacognostic evaluation of Achyranthes coynei: Leaf
645
Pharmacognostic Evaluation of Maesobotrya barteri (Baill) Hutch and Maesobotrya dusenii Pax (Euphorbiaceae) Leaves
646
Pharmacognostic Evaluation of Oxalis pes-caprae L. (Family Oxalidaceae)
647
Pharmacognostic evaluation of the leaves of Mitracarpus scaber Zucc (Rubiaceae)
648
Pharmacognostic Evaluation of the Leaves of Secamone afzelii (Schult) K Schum (Asclepiadaceae)
649
Pharmacognostic Investigation of the Leaves and Stems of Viburnum erubescens Wall.ex DC
650
Pharmacognostic Profile and Screening of Anti-Proliferative Potential of Methanolic Extract of Tripterygium wilfordii Plant on WRL-68 Cell Line and Function of Polycystin‐1
651
Pharmacognostic Standardization and Chromatographic Fingerprint Analysis on Triterpenoidal Constituents of the Medicinally Important Plant Artocarpus heterophyllus by High‑Performance Thin Layer Chromatography Technique
652
Pharmacognostic study of Argyreia pilosa stem
653
Pharmacognostic, Physicochemical and Phytochemical Investigations on Aerial Parts of Argemone mexicana L.
654
Pharmacognostical and physico-chemical evaluations of Cardiospermum halicacabum L. seeds
655
Pharmacognostical Sources of Popular Medicine To Treat Alzheimer’s Disease
656
Pharmacognostical study of Chorisia insignis HBK. grown in Egypt
657
Pharmacognostical, physico-chemical and contamination studies of polyherbal formulation “qurse pudina”
658
Pharmacokinetic analysis by high-performance liquid chromatography of intravenous nordihydroguaiaretic acid in the mouse
659
Pharmacokinetic analysis in serum of genistein administered subcutaneously to neonatal mice
660
Pharmacokinetic analysis of ductal carcinoma in situ of the breast using dynamic MR mammography
661
Pharmacokinetic analysis of glioma compartments with dynamic Gd-DTPA-enhanced magnetic resonance imaging
662
Pharmacokinetic analysis of nicotine when using non-combustion inhaler type of tobacco product in Japanese adult male smokers
663
Pharmacokinetic and biodistribution properties of poly(ethylene glycol)–protein conjugates
664
Pharmacokinetic and drug interaction studies of Pefloxacin with paracetamol (NNAID) in healthy volunteers in Pakistan
665
Pharmacokinetic and excretion study of three secoiridoid glycosides and three flavonoid glycosides in rat by LC–MS/MS after oral administration of the Swertia pseudochinensis extract
666
Pharmacokinetic and fetal cardiovascular effects of enalaprilat administration to maternal rhesus macaques, ,
667
Pharmacokinetic and Hemodynamic Responses to Oral Sildenafil During Invasive Testing in Children With Pulmonary Hypertension
668
Pharmacokinetic and milk penetration of a difloxacin long-acting poloxamer gel formulation with carboxy-methylcellulose in lactating goats
669
Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part 1. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers
670
Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Doseproportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers
671
Pharmacokinetic and Pharmacodynamic Comparison of Controlled-Release Carvedilol and Immediate-Release Carvedilol at Steady State in Patients with Hypertension
672
Pharmacokinetic and pharmacodynamic integration and modelling of marbofloxacin in calves for Mannheimia haemolytica and Pasteurella multocida
673
Pharmacokinetic and pharmacodynamic modelling of marbofloxacin administered alone and in combination with tolfenamic acid in goats
674
Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation
675
Pharmacokinetic and pharmacodynamic properties of the new AEDs: A review article.
676
Pharmacokinetic and tissue distribution of doxycycline in broiler chickens pretreated with either: Diclazuril or halofuginone
677
Pharmacokinetic and toxicological data of spirolides after oral and intraperitoneal administration
678
Pharmacokinetic and tumour-photosensitizing properties of methoxyphenyl porphyrin derivative
679
Pharmacokinetic applicability of a validated liquid chromatography tandem mass spectroscopy method for orally administered curcumin loaded solid lipid nanoparticles to rats
680
Pharmacokinetic application of fuzzy structure identification and reasoning
681
Pharmacokinetic behavior and pharmacokinetic/pharmacodynamic integration of marbofloxacin after subcutaneous administration in goats
682
Pharmacokinetic behavior of marbofloxacin after intravenous, subcutaneous and intramuscular administrations in llamas (Lama glama)
683
Pharmacokinetic Behavior of Phenytoin in Head Trauma and Cerebrovascular Accident Patients in an Iranian Population
684
Pharmacokinetic Behavior of Theophylline following PEEP in Critically Ill Patients with Acute Lung Injury
685
Pharmacokinetic behaviour of ACP gel, an autocrosslinked hyaluronan derivative, after intraperitoneal administration
686
Pharmacokinetic behaviour of enrofloxacin in greater rheas following a single-dose intramuscular administration
687
Pharmacokinetic characterization of ginsenoside Rh2, an anticancer nutrient from ginseng, in rats and dogs
688
Pharmacokinetic comparisons of different combinations of Shaoyao-Gancao-Decoction in rats: Simultaneous determination of ten active constituents by HPLC–MS/MS
689
Pharmacokinetic comparisons of puerarin, daidzin and the glucuronide metabolite of puerarin after administration of total flavonoid from Gegen alone and total flavonoid from Gegen combined with total saponin from Sanqi in rats under different physiologica
690
Pharmacokinetic Computer Simulations of the Relationship Between In Vivo and In Vitro Neuroreceptor Subtype Selectivity of Radioligands
691
Pharmacokinetic considerations for targeted drug delivery
692
Pharmacokinetic differences between ethnic groups
693
Pharmacokinetic differences between ethnic groups
694
Pharmacokinetic dosing of aminoglycosides: a controlled trial
695
Pharmacokinetic Drug Food Interaction Study of Nateglinide and Pomegranate Fruit Juice
696
Pharmacokinetic drug‑drug interaction and their implication in clinical management
697
Pharmacokinetic Effect of MDR Gene Polymorphism rs2032582 on the Therapeutic Response in Iraqi Patients with Acute Myeloid Leukemia
698
Pharmacokinetic enhancement of marbofloxacin by alpha-1-monolaurin pre-treatment in broiler chickens
699
PHARMACOKINETIC EVALUATION OF CLARITHROMYCIN ORAL CONTROLLED RELEASE MATRIX TABLETS FOR DESIRED BIOAVAILABILITY AND IMPROVED PATIENT COMPLIANCE
700
Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography–mass spectrometry
701
Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug
702
Pharmacokinetic evaluation of tramadol and its major metabolites after single oral sustained tablet administration in the dog: a pilot study
703
Pharmacokinetic Evaluation of Two Doses of Aminophylline/Theophylline Administered as Multiple Intermittent Infusions to Iranian Apneic Premature Neonates
704
Pharmacokinetic Interaction of Salbutamol Coadministered with Vasicine Isolated from Adhathoda vasica on Rabbit
705
Pharmacokinetic Interaction Study for Simvastatin and Parsley and Its Plasma Quantification Using LC-MS: A Focus on Drug Metabolic Enzymes
706
Pharmacokinetic interactions between chloroquine, sulfadoxine and pyrimethamine and their bioequivalence in a generic fixed-dose combination in healthy volunteers in Uganda
707
Pharmacokinetic Interactions between Intravenous Ciprofloxacin and Oral Ferrous Sulfate
708
Pharmacokinetic interactions: The effects of selected herbal extracts on permeation of P-glycoprotein substrate drugs across excised pig intestinal tissue
709
Pharmacokinetic Investigation to Study the In Vivo Bioavailability of Thiolated Chitosan Based Repaglinide Buccal Tablets
710
Pharmacokinetic model for in vivo/in vitro correlation of intravitreal drug delivery
711
Pharmacokinetic model of daily selenium intake from contaminated seafood in Taiwan
712
Pharmacokinetic model of dioxin and furan levels in adipose tissue from Sawmill work involving chlorophenate fungicides
713
Pharmacokinetic of ALA and h-ALA induced porphyrins in the models Mycobacterium phlei and Mycobacterium smegmatis
714
Pharmacokinetic of sulfaclozine in broiler chickens
715
Pharmacokinetic optimization of 3-amino-6-chloropyrazinone acetamide thrombin inhibitors. implementation of P3 pyridine N-Oxides to deliver an orally bioavailable series containing P1 N-Benzylamides
716
Pharmacokinetic Parameters and OverResponsiveness of Iranian Population to Propranolol
717
Pharmacokinetic Parameters and Over-Responsiveness of Iranian Population to Propranolol
718
Pharmacokinetic parameters as a potential predictor of response to pharmacotherapy in benign prostatic hyperplasia: a preclinical trial using dynamic contrast-enhanced MRI
719
Pharmacokinetic parameters of valproic acid and carbamazepine from routinely collected data: Influence of patient characteristics
720
Pharmacokinetic profile of a sustained-delivery system for physostigmine in rats
721
Pharmacokinetic Profile of Controlled-Release Carvedilol in Patients with Left Ventricular Dysfunction Associated with Chronic Heart Failure or After Myocardial Infarction
722
Pharmacokinetic Profile of Plasma Levobupivacaine Following Fascia Iliaca Compartment Block for Proximal Femoral Fracture in Older Patient
723
Pharmacokinetic profile of recombination human insulin-like growth factor binding protein-1 in athymic mice
724
Pharmacokinetic Properties of a New Controlled-Release Formulation of Carvedilol
725
Pharmacokinetic studies and human absorbed dose estimation of 68Ga-(4 {[(bis (phosphonomethyl)) carbamoyl] methyl}-7,10-bis(carboxymethy l) -1,4,7,10-tetraazacyclododec-1-yl) acetic acid
726
Pharmacokinetic studies in cancer chemotherapy: Usefulness in clinical practice
727
Pharmacokinetic Studies of Enrofloxacin in Yak after Intramuscular Administration
728
Pharmacokinetic studies of metformin and glibenclamide in normal human volunteers
729
Pharmacokinetic studies of protein drugs: Past, present and future
730
Pharmacokinetic Studies of Rifampicin in Healthy Volunteers and Tuberculosis Patients
731
Pharmacokinetic studies on 5-aminolevulinic acid-induced protoporphyrin IX accumulation in tumours and normal tissues
732
Pharmacokinetic Studies on Metoprolol - Eudragit Matrix Tablets and Bioequivalence Consideration with Mepressor®
733
Pharmacokinetic Studies on Oximes in Organophosphate Poisoning: A Mini Review
734
Pharmacokinetic Study of a Capsule-based Chronomodulated Drug Delivery System of Salbutamol Sulphate in Rabbits
735
Pharmacokinetic study of acyl-protected hydroxylamine probe, 1-acetoxy-3-carbamoyl-2,2,5,5-tetramethylpyrrolidine, for in vivo measurements of reactive oxygen species
736
Pharmacokinetic study of calenduloside E and its active metabolite oleanolic acid in beagle dog using liquid chromatography–tandem mass spectrometry
737
Pharmacokinetic study of carbamazepine and its carbamazepine 10,11-epoxide metabolite in a group of female epileptic patients under chronic treatment
738
PHARMACOKINETIC STUDY OF CEPHRADINE IN PAKISTANI HEALTHY MALE VOLUNTEERS
739
Pharmacokinetic study of dicloxacillin sodium following intravenous and intramuscular administration to pigs
740
Pharmacokinetic study of dl-tetrahydropalmatine patches by UPLC–MS/MS in rabbits
741
Pharmacokinetic study of ellagic acid in rat after oral administration of pomegranate leaf extract
742
Pharmacokinetic study of free mangiferin in rats by microdialysis coupled with microbore high-performance liquid chromatography and tandem mass spectrometry
743
Pharmacokinetic study of furosemide incorporated PLGA microspheres after oral administration to rat
744
Pharmacokinetic study of HS061, a new human insulin, in non-diabetic rat using ultra performance liquid chromatography–tandem mass spectrometry
745
Pharmacokinetic study of levofloxacin in rat blood and bile by microdialysis and high-performance liquid chromatography
746
Pharmacokinetic study of mangiferin in human plasma after oral administration
747
Pharmacokinetic study of melamine in rhesus monkey after a single oral administration of a tolerable daily intake dose
748
Pharmacokinetic study of multiple active constituents from Kushen–Gancao Decoction after oral administration in rat by HPLC–MS/MS
749
Pharmacokinetic study of mycophenolic acid in Iranian kidney transplant patients.
750
Pharmacokinetic Study of Nifedipine in Healthy Adult Male Human Volunteers
751
Pharmacokinetic study of niosome-loaded insulin in diabetic rats
752
Pharmacokinetic study of orphenadrine using high-performance liquid chromatography–tandem mass spectrometry (HPLC–MS/MS)
753
Pharmacokinetic study of three cardiovascular drugs by high-performance liquid chromatography using pre-column derivatization with 9,10-anthraquinone-2-sulfonyl chloride
754
Pharmacokinetic variability of extended interval tobramycin in burn patients
755
PHARMACOKINETIC VARIATIONS OF OFLOXACIN IN NORMAL AND FEBRILE RABBITS
756
Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies
757
Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients
758
Pharmacokinetic/pharmacodynamic modeling of antitumor agents encapsulated into liposomes
759
Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology
760
Pharmacokinetic-pharmacodynamic indices of enrofloxacin in Escherichia coli O78/H12 infected chickens
761
Pharmacokinetic-Pharmacodynamic Modeling: Why?
762
Pharmacokinetic–pharmacodynamic models for categorical toxicity data
763
Pharmacokinetics after intravenous, intramuscular and subcutaneous administration of moxifloxacin in sheep
764
Pharmacokinetics after pulmonary artery perfusion with gemcitabine
765
Pharmacokinetics Alterations of Midazolam Infusion versus Bolus Administration in Mechanically Ventilated Critically Ill Patients
766
Pharmacokinetics and Bioavailability Comparison of two oral Tablet Formulations of Escitalopram 20 mg: A Single-Dose, Open-Label, Two-Period Crossover Study in Healthy Indian Adult Subjects
767
Pharmacokinetics and bioavailability of diisopropanolamine (DIPA) in rats following intravenous or dermal application
768
Pharmacokinetics and bioavailability study of polydatin in rat plasma by using a LC–MS/MS method
769
Pharmacokinetics and Biodistribution of Pegylated Methotrexate after IV Administration to Mice
770
Pharmacokinetics and Biodistribution of Rhopalurus junceus Scorpion Venom in Tumor-Bearing Mice after Intravenous and Oral Administration
771
Pharmacokinetics and Bioequivalence of Methotrexate in Human Plasma Studied by Liquid Chromatography-Mass Spectrometry (LC-MS)
772
Pharmacokinetics and Bioequivalence Study of Two Formulations of Cefixime in Healthy Male Volunteers
773
Pharmacokinetics and brain distribution of unbound levamisole in the anesthetized rats using microdialysis and microbore column liquid chromatography Original Research Article
774
Pharmacokinetics and brain penetration of LF-3-88, (2-[5-[5-(2(S)-azetidinylmethoxyl)-3-pyridyl]-3-isoxazolyl]ethanol), a selective α4β2-nAChR partial agonist and promising antidepressant
775
Pharmacokinetics and Dosage Regimen of Cefepime following Single Dose Intravenous Administration in Calves
776
Pharmacokinetics and Dosage Regimen of Cefpirome in Febrile Cross-Bred Calves
777
PHARMACOKINETICS AND DOSAGE REGIMEN OF CIPROFLOXACIN FOLLOWING SINGLE INTRAMUSCULAR ADMINISTRATION IN TEDDY GOATS
778
Pharmacokinetics and dosimetry of 188Re-pharmaceuticals
779
Pharmacokinetics and Effects of Alkalization after Intravenous Administration of Eltenac in Horses
780
Pharmacokinetics and Effects of Alkalization During Oral and Intravenous Administration of Naproxen in Horses
781
Pharmacokinetics and effects of cetirizine in horses with insect bite hypersensitivity
782
Pharmacokinetics and efficacy of intravenous and extradural tramadol in dogs
783
Pharmacokinetics and efficacy of oral versus intravenous mixed-micellar phylloquinone (vitamin K1) in severe acute liver disease
784
Pharmacokinetics and ex vivo pharmacodynamics of cefquinome in porcine serum and tissue cage fluids
785
Pharmacokinetics and excretion study of sophoricoside and its metabolite in rats by liquid chromatography tandem mass spectrometry
786
Pharmacokinetics and hemodynamic effects of the phosphodiesterase III inhibitor saterinone in patients with chronic heart failure
787
Pharmacokinetics and hepatotoxicity of diclofenac using an isolated perfused rat liver
788
Pharmacokinetics and in vivo chemosuppressive activity studies on cryptolepine hydrochloride and cryptolepine hydrochloride-loaded gelatine nanoformulation designed for parenteral administration for the treatment of malaria
789
Pharmacokinetics and interaction pharmacodynamics of dexmedetomidine in humans
790
Pharmacokinetics and intramuscular bioavailability of difloxacin in dromedary camels (Camelus dromedarius)
791
Pharmacokinetics and metabolic effects of triamcinolone acetonide and their possible relationships to glucocorticoid-induced laminitis in horses
792
Pharmacokinetics and metabolism of 3,4-dichlorophenyl-propenoyl-sec.-butylamine in rats by high performance liquid chromatography–ion trap mass spectrometry
793
Pharmacokinetics and metabolism of single oral doses of trovafloxacin
794
Pharmacokinetics and metabolism studies on (3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy) pyrazolo[1,5-d][1,2,4]triazine, a functionally selective GABAA α5 inverse agonist for cognitive dysfunction
795
Pharmacokinetics and metabolite identification of a novel VEGFR-2 and Src dual inhibitor 6-chloro-2-methoxy-N-(2-methoxybenzyl) acridin-9-amine in rats by liquid chromatography tandem mass spectrometry
796
Pharmacokinetics and milk penetration of moxifloxacin after intramuscular administration to lactating goats
797
Pharmacokinetics and milk penetration of moxifloxacin after intravenous and subcutaneous administration to lactating goats
798
Pharmacokinetics and Molecular Docking Studies of Uridine Derivatives as SARSCOV-2 Mpro Inhibitors
799
Pharmacokinetics and Pharmacodynamic Effects of Flunixin after Intravenous, Intramuscular and Oral Administration to Dairy Goats
800
Pharmacokinetics and pharmacodynamic effects of tolazoline following intravenous administration to horses
801
Pharmacokinetics and pharmacodynamics of d-chlorpheniramine following intravenous and oral administration in healthy Thoroughbred horses
802
Pharmacokinetics and Pharmacodynamics of Gliclazide from Immediate and Modified Release Formulation Tablets in Rats
803
Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors
804
Pharmacokinetics and pharmacodynamics of subcutaneous heparin during the early third trimester of pregnancy
805
Pharmacokinetics and pharmacodynamics of tetra(m-hydroxyphenyl)chlorin in the hamster cheek pouch tumor model: comparison with clinical measurements
806
Pharmacokinetics and pharmacodynamics of torasemide and furosemide in patients with diuretic resistant ascites
807
Pharmacokinetics and pharmacogenomics in breast cancer chemotherapy
808
Pharmacokinetics and pharmacogenomics in esophageal cancer chemoradiotherapy
809
Pharmacokinetics and pharmacogenomics in gastric cancer chemotherapy
810
Pharmacokinetics and PK-PD modelling of danofloxacin in camel serum and tissue cage fluids
811
Pharmacokinetics and radiation dosimetry estimation of O-(2-[18F]fluoroethyl)-image-tyrosine as oncologic PET tracer
812
Pharmacokinetics and residual behaviour in milk of oxytetracycline in cows following administration of uterine pessaries
813
Pharmacokinetics and residues of a new oral amoxicillin formulation in piglets: A preliminary study
814
Pharmacokinetics and residues of tetracycline in crucian carp muscle using capillary electrophoresis on-line coupled with electrochemiluminescence detection
815
Pharmacokinetics and safety of TP10, soluble complement receptor 1, in infants undergoing cardiopulmonary bypass
816
Pharmacokinetics and tissue and milk disposition of Tilmicosin in sheep after single administrations
817
Pharmacokinetics and tissue distribution of a novel marine fibrinolytic compound in Wistar rat following intravenous administrations
818
Pharmacokinetics and Tissue Distribution of Antimony(v) after Multiple Intramuscular Administrations in the Hamster
819
Pharmacokinetics and tissue distribution of bovine testicular hyaluronidase and vinblastine in mice: an attempt to optimize the mode of adjuvant hyaluronidase administration in cancer chemotherapy
820
Pharmacokinetics and tissue distribution of docetaxel by liquid chromatography–mass spectrometry: Evaluation of folate receptor-targeting amphiphilic copolymer modified nanostructured lipid carrier
821
Pharmacokinetics and tissue distribution of the antileukaemic organoarsenicals arsthinol and melarsoprol in mice
822
Pharmacokinetics and Tolerability of Iopromide 240 After Lumbar Myelography
823
Pharmacokinetics in gene delivery
824
Pharmacokinetics in pregnancy
825
Pharmacokinetics in the elderly
826
Pharmacokinetics in the newborn
827
Pharmacokinetics of a long-acting oxytetracycline-polyethylene glycol formulation in horses
828
Pharmacokinetics of a Mono-pyridinium-mono-aldoxime (K-347), a Potential Antidote in Organophosphate Poisoning
829
Pharmacokinetics of a tri-glucoconjugated 5,10,15-(meta)-trihydroxyphenyl-20-phenyl porphyrin photosensitizer for PDT. A single dose study in the rat
830
Pharmacokinetics of albendazole sulfoxide enantiomers administered in racemic form and separately in rats
831
Pharmacokinetics of alprazolam in elderly patients with multiple diseases
832
Pharmacokinetics of aminomethylpropanol in rats following oral and a novel dermal study design
833
Pharmacokinetics of Amoxicillin/Clavulanic Acid Combination after Oral Administration of New Suspension Formulations in Human Volunteers
834
Pharmacokinetics of an ampicillin–sulbactam combination after intravenous and intramuscular administration to neonatal calves
835
Pharmacokinetics of anticancer drugs, plasmid DNA, and their delivery systems in tissue-isolated perfused tumors
836
Pharmacokinetics of betamethasone after maternal or fetal intramuscular administration
837
Pharmacokinetics of buprenorphine after intravenous administration of clinical doses to dogs
838
PHARMACOKINETICS OF CALCIUM FROM CALCIUM SUPPLEMENTS IN HEALTHY VOLUNTEERS
839
Pharmacokinetics of calycopterin and xanthmicrol, two polymethoxylated hydroxyflavones with anti-angiogenic activities from Dracocephalum kotschyi Bioss
840
Pharmacokinetics of Cefepime Following Intravenous and Intramuscular Administration in Sheep
841
Pharmacokinetics of ceftazidime after intravenous and intramuscular administration to domestic cats
842
Pharmacokinetics of ceftazidime in buffalo calves following intravenous and intramuscular administration
843
Pharmacokinetics of ceftiofur sodium in equine pregnancy
844
Pharmacokinetics of ceftriaxone in buffalo calves (Bubalus bubalis) following intravenous and intramuscular administration
845
Pharmacokinetics of Cephalexin in the Horse After Intravenous and Intramuscular Administration of Two Formulations
846
Pharmacokinetics of ciprofloxacin in bath medicated hybrid tilapias using enzyme linked immunosorbent assay (ELISA)
847
PHARMACOKINETICS OF CIPROFLOXACIN IN NORMAL RABBITS AND CHANGES OBSERVED IN INDUCED DEHYDRATED STATE
848
Pharmacokinetics of ciprofloxacin in sheep following intravenous and subcutaneous administration
849
Pharmacokinetics of ciprofloxacin in the rat and its interaction with cyclosporin A: a microdialysis study Original Research Article
850
Pharmacokinetics of Clozapine: An Investigate the Potential Molecular Mechanisms of Action
851
Pharmacokinetics of combined doxorubicin and paclitaxel in mice
852
Pharmacokinetics of conjugated metabolites in rat plasma after oral administration of tectoridin
853
Pharmacokinetics of curcumin-loaded PLGA and PLGA–PEG blend nanoparticles after oral administration in rats
854
Pharmacokinetics of dexamethasone after intravenous and intramuscular administration in broiler chickens
855
Pharmacokinetics of dexamethasone after intravenous and intramuscular administration in pigs
856
Pharmacokinetics of dexamethasone and its relationship to dexamethasone suppression test outcome in depressed patients and healthy control subjects
857
Pharmacokinetics of Dextran-70 in patients with cirrhosis and ascites undergoing therapeutic paracentesis
858
Pharmacokinetics of Diclofenac in Sheep Following Intravenous and Intramuscular Administration
859
Pharmacokinetics of Diclofenac in Sheep Following Intravenous and Intramuscular Administration
860
Pharmacokinetics of dl-praeruptorin A after single-dose intravenous administration to rats with liver cirrhosis
861
Pharmacokinetics of Doramectin and Ivermectin After Oral Administration in Horses*
862
Pharmacokinetics of doramectin in lactating dairy sheep and suckling lambs Original Research Article
863
Pharmacokinetics of doxycycline in sheep after intravenous and oral administration
864
Pharmacokinetics of enrofloxacin and flunixin meglumine and interactions between both drugs after intravenous co-administration in healthy and endotoxaemic rabbits
865
Pharmacokinetics of Enrofloxacin and Its Active Metabolite Ciprofloxacin and Its Interaction With Diclofenac After Intravenous Administration in Buffalo Calves
866
Pharmacokinetics of Enrofloxacin and its Metabolite Ciprofloxacin in Goats given Enrofloxacin Alone and in Combination with Probenecid
867
Pharmacokinetics of enrofloxacin and the rate of formation of its metabolite ciprofloxacin following intravenous and intramuscular single dose administration to male buffalo calves
868
Pharmacokinetics of ergosterol in rats using rapid resolution liquid chromatography–atmospheric pressure chemical ionization multi-stage tandem mass spectrometry and rapid resolution liquid chromatography/tandem mass spectrometry
869
Pharmacokinetics of erythromycin after intravenous, intramuscular and oral administration to cats
870
Pharmacokinetics of exogenous gonadotropin and ovarian response in in vitro fertilization
871
Pharmacokinetics of fexofenadine in healthy Taiwanese volunteers
872
Pharmacokinetics of fleroxacin in horses
873
Pharmacokinetics of fluoroquinolones in critical care patients: A bio-analytical HPLC method for the simultaneous quantification of ofloxacin, ciprofloxacin and moxifloxacin in human plasma
874
Pharmacokinetics of gadoversetamide injection, a gadolinium-based contrast agent, in pediatric patients
875
Pharmacokinetics of ganoderic acid D and its main metabolite by liquid chromatography–tandem mass spectrometry
876
Pharmacokinetics of Gefodizime in Patients with Various Degrees of Renal Failure
877
Pharmacokinetics of gentamicin in mares in late pregnancy and early lactation
878
Pharmacokinetics of hydrocodone and hydromorphone after oral hydrocodone in healthy Greyhound dogs
879
Pharmacokinetics of HZ08 in rats by liquid chromatography–tandem mass spectrometry
880
Pharmacokinetics of ingested fluoride: Lack of effect of chemical compound
881
Pharmacokinetics of Intravascularly Administered 65Zinc in Channel Catfish (Ictalurus punctatus)
882
Pharmacokinetics of intravenous and intramuscular parecoxib in healthy Beagles
883
Pharmacokinetics of ionized versus total magnesium in subjects with preterm labor and preeclampsia
884
Pharmacokinetics of kadsurenone and its interaction with cyclosporin A in rats using a combined HPLC and microdialysis system
885
Pharmacokinetics of kakkalide and its main metabolites in rat plasma determined by HPLC-DAD and LC–MSn
886
Pharmacokinetics of ketoprofen enantiomers after intravenous administration of racemate in camels: effect of gender
887
Pharmacokinetics of L-arginine during chronic administration to patients with hypercholesterolaemia
888
Pharmacokinetics of liposomal aerosolized cyclosporine A for pulmonary immunosuppression
889
Pharmacokinetics of lithium in rat brain regions by spectroscopic imaging
890
Pharmacokinetics of marbofloxacin after intravenous and intramuscular administration to ostriches
891
Pharmacokinetics of marbofloxacin after single intravenous and repeat oral administration to cats
892
Pharmacokinetics of melamine in pigs following intravenous administration
893
Pharmacokinetics of methylphenidate after oral administration of immediate and sustained-release preparations in Beagle dogs
894
Pharmacokinetics of metronidazole in horses after intravenous, rectal and oral administration
895
Pharmacokinetics of metronidazole in rat blood, brain and bile studied by microdialysis coupled to microbore liquid chromatography
896
Pharmacokinetics of mirtazapine and its main metabolites after single intravenous and oral administrations in rats at two dose rates
897
Pharmacokinetics of Mirtazapine and Its Main Metabolites after Single Oral Administration in Fasting/Fed Horses
898
Pharmacokinetics of mirtazapine and its main metabolites in Beagle dogs: A pilot study
899
Pharmacokinetics of oral gabapentin alone or co-administered with meloxicam in ruminant beef calves
900
Pharmacokinetics of oral gabapentin in greyhound dogs
901
Pharmacokinetics of oral valacyclovir and acyclovir in late pregnancy, , ,
902
Pharmacokinetics of pefloxacin mesylate in human urine using capillary electrophoresis electrochemiluminescence detection
903
Pharmacokinetics of Photogem using fluorescence monitoring in Wistar rats
904
Pharmacokinetics of piperine after oral administration of Sahastara remedy capsules in healthy volunteers
905
Pharmacokinetics of prostaglandins
906
Pharmacokinetics of protein-unbound linezolid in the blood and the mechanism of hepatobiliary excretion in the rat Original Research Article
907
Pharmacokinetics of protocatechuic acid in mouse and its quantification in human plasma using LC–tandem mass spectrometry
908
Pharmacokinetics of sodium and trihydrate amoxicillin after intravenous and intramuscular administration in llamas (Lama glama)
909
Pharmacokinetics of sterically stabilized hexadecylphosphocholine liposomes versus conventional liposomes and free hexadecylphosphocholine in tumor-free and human breast carcinoma bearing mice
910
Pharmacokinetics of sterically stabilized hexadecylphosphocholine liposomes versus conventional liposomes and free hexadecylphosphocholine in tumor-free and human breast carcinoma bearing mice
911
Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies
912
Pharmacokinetics of Sulpiride After Intravenous, Intramuscular, and Oral Single-Dose Administration in Nurse Mares
913
Pharmacokinetics of Tetracycline and Tetracycline Loaded Nanoemulsion Formula in Rabbits
914
Pharmacokinetics of tetracycline hydrochloride in fat-tailed sheep
915
Pharmacokinetics of the low molecular weight heparin dalteparin in cats
916
Pharmacokinetics of the novel atypical opioid tapentadol after intravenous, intramuscular and subcutaneous administration in cats
917
Pharmacokinetics of the novel atypical opioid tapentadol following oral and intravenous administration in dogs
918
Pharmacokinetics of the potent redox-modulating manganese porphyrin, MnTE-2-PyP5+, in plasma and major organs of B6C3F1 mice
919
Pharmacokinetics of the Thymidine Analog 2-Fluoro-5[14C]-methy1-1-beta-D-arabinofuranosyluracil ([14C]FMAU) in Rat Prostate Tumor Cells
920
Pharmacokinetics of tobramycin in ducks and sex-related differences
921
Pharmacokinetics of Tramadol after Epidural Administration in Horses
922
Pharmacokinetics of Tramadol and its Metabolites M1, M2 and M5 in Horses Following Intravenous, Immediate Release (Fasted/Fed) and Sustained Release Single Dose Administration
923
Pharmacokinetics of Tramadol and Its Metabolites M1, M2, and M5 in Donkeys after Intravenous and Oral Immediate Release Single-Dose Administration
924
Pharmacokinetics of tulathromycin in lactating goats
925
Pharmacokinetics of two different delivery regimens of doxorubicin in isolated hyperthermic limb perfusion
926
PHARMACOKINETICS OF UMF-078, A CANDIDATE ANTIFILARIAL DRUG, IN INFECTED DOGS
927
Pharmacokinetics of zonisamide in perinatal period
928
Pharmacokinetics Studies of some Diaryl Pyrimidinamine Derivatives as Anti-Cancer Agent: In-Silico Drug Design and Molecular Docking
929
Pharmacokinetics study of chitosan-coated liposomes containing sumatriptan in the treatment of migraine
930
Pharmacokinetics, bioavailability and tissue residues of [14C]isometamidium in non-infected and Trypanosoma congolense-infected Boran cattle
931
Pharmacokinetics, biodistribution, efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel
932
Pharmacokinetics, dosage regimen and in vitro plasma protein binding of intramuscular levofloxacin in buffalo calves
933
Pharmacokinetics, efficacy, and safety of analgesia with a focus on tramadol HCl
934
Pharmacokinetics, immunogenicity and anticancer efficiency of Aspergillus flavipes l-methioninase
935
Pharmacokinetics, pharmacodynamics and toxicity of a combination of metoprolol succinate and telmisartan in Wistar albino rats: Safety profiling
936
Pharmacokinetics, safety, and effects on exercise performance of l-arginine α-ketoglutarate in trained adult men
937
Pharmacokinetics, tissue distribution and excretion of a new photodynamic drug deuxemether
938
Pharmacokinetics, tissue distribution and excretion study of dictamnine, a major bioactive component from the root bark of Dictamnus dasycarpus Turcz. (Rutaceae)
939
Pharmacokinetics, urinary excretion and plasma protein binding of 2,3-butanedione monoxime in goats
940
Pharmacokinetics, urinary excretion and plasma protein binding of pralidoxime in goats
941
Pharmacokmetics and oral bioavailability of a doxycycline formulation (DOXYCYCLINE 75%) in nonfasted young pigs
942
Pharmacokmetics and oral bioavailability of a doxycycline formulation (DOXYCYCLINE 75%) in nonfasted young pigs
943
Pharmacoligical characterization of the iranian Cerastes cerastes gasperettii (Reptilia: Ophidia: Viperidae) venom
944
Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription
945
Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer
946
Pharmacologic agents for the treatment of acute bipolar mania
947
Pharmacologic alterations in human type I atrial flutter cycle length and monophasic action potential duration Evidence of fully excitable gap in the reentrant circuit
948
Pharmacologic and nonpharmacologic options to maintain sinus rhythm: guideline-based and new approaches
949
Pharmacologic and Therapeutic Differences Among Calcium Channel Antagonists: Profile of Mibefradil, a New Calcium Antagonist
950
Pharmacologic Approaches Against Advanced Glycation End Products (AGEs) in Diabetic Cardiovascular Disease
951
Pharmacologic approaches to rhythm versus rate control in atrial fibrillation—where are we now?
952
Pharmacologic approaches to therapy for vasovagal syncope
953
Pharmacologic Characterization of Wool Dust Extract in Isolated Guinea Pig Trachea
954
Pharmacologic evidence for a parasympathetic role in seizure-induced neurocardiac regulatory abnormalities
955
Pharmacologic Inhibition of MALT1 Protease by Phenothiazines as a Therapeutic Approach for the Treatment of Aggressive ABC-DLBCL
956
Pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure
957
Pharmacologic Inhibition of the Anaphase-Promoting Complex Induces A Spindle Checkpoint-Dependent Mitotic Arrest in the Absence of Spindle Damage
958
Pharmacologic management of childhood hypertension: current status, future challenges
959
Pharmacologic Management of Overactive Bladder: Practical Options for the Primary Care Physician
960
Pharmacologic modulation of neutrophil functions
961
Pharmacologic modulation of the collateral vascular resistance in acute and chronic coronary occlusion assessed by intracoronary blood flow velocity analysis
962
Pharmacologic myocardial protection during percutaneous transluminal coronary angioplasty by intracoronary application of dipyridamole: Impact on hemodynamic function and left ventricular performance
963
Pharmacologic myocardial regeneration
964
Pharmacologic Options for Aggressive Low-Density Lipoprotein Cholesterol Lowering: Benefits Versus Risks
965
Pharmacologic plaque passivation for the reduction of recurrent cardiac events in acute coronary syndromes
966
Pharmacologic preconditioning of estrogen by activation of the myocardial adenosine triphosphate-sensitive potassium channel in patients undergoing coronary angioplasty
967
Pharmacologic preservation of the hemostatic system during cardiac surgery
968
Pharmacologic prevention of poterior capule opacification: in vitro effect of preervative-free lidocaine 1 % on len epithelial cell
969
Pharmacologic profile of survivors of acute myocardial infarction at United States academic hospitals
970
Pharmacologic Prophylaxis and Treatment of Venous Thromboembolism after Knee Arthroplasty
971
Pharmacologic Relevance of K+Channel Remodeling in Atrial Fibrillation
972
Pharmacologic strategies for augmenting cognitive performance in schizophrenia
973
Pharmacologic Strategies for Prevention of Atrial Fibrillation After Open Heart Surgery
974
Pharmacologic stress echocardiography: can we forget “state-of-the-art” protocols?
975
Pharmacologic stress testing for coronary disease diagnosis: A meta-analysis
976
Pharmacologic stress-induced regional myocardial blood flow heterogeneity and left ventricular wall thickening abnormality: Comparison of intravenous adenosine with dipyridamole in a model of critical coronary stenosis, , ,
977
Pharmacologic support with high-energy phosphate preservation in the postischemic neonatal heart
978
Pharmacologic therapies after myocardial infarction
979
Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations
980
Pharmacologic treatment of atherosclerosis: beyond lipid-lowering therapy
981
Pharmacologic treatment of hypertension in the Department of Veterans Affairs during 1995 and 1996
982
Pharmacologic treatment of schizophrenia
983
Pharmacologic Treatment of Wet Type Age-related Macular Degeneration; Current and Evolving Therapies
984
Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma
985
Pharmacologic versus direct-current electrical cardioversion of atrial flutter and fibrillation
986
Pharmacologic versus flow-mediated assessments of peripheral vascular endothelial vasodilatory function in humans
987
Pharmacologic Vitreolysis
988
Pharmacological Action of Mentha piperita on Lipid Profile in Fructose-Fed Rats
989
Pharmacological action of tick saliva upon haemostasis and the neutralization ability of sera from repeated infested hosts
990
Pharmacological Activities of Hypnea musciformis
991
Pharmacological activity of 2% aqueous acetic acid extract of Alhagi maurorum roots
992
Pharmacological algorithms for treatment resistant depression in children and adolescents
993
Pharmacological analysis of ovarial patency in Heliothis virescens
994
Pharmacological and Antioxidant Activities of Rhus coriaria L. (Sumac)
995
Pharmacological and biochemical effects of Ginkgo biloba extract on learning, memory consolidation and motor activity in old rats
996
Pharmacological and biological evaluation of extracts from Gratiola officinalis L. (Scrophulariaceae)
997
Pharmacological and cognitive-behavioral approaches in the treatment of childhood depression: A review and critique
998
Pharmacological and computational evaluation of Sapodilla and its constituents for therapeutic potential in hyperactive gastrointestinal disorders
999
Pharmacological and Medical Effect of Modified Skin Grafting Method in Patients with Chronic and Severe Neck Burns
1000
Pharmacological and Medicinal Aspects of the Verses Containing Fig (At-tin) in Holy Quran
